BusinessSPR Therapeutics® Secures $25 Million in Series C FinancingBy Nasdaq OMXSep 12, 2017, 12:03 PM UTC
BusinessOpioid Concerns and Work Interference Cited as Top Reasons to Delay Knee Replacement SurgeryBy Nasdaq OMXAug 3, 2017, 3:03 PM UTC
BusinessSPR Therapeutics Awarded $6M Contract From the United States Department of Defense to Advance Non-Opioid Pain Relief TherapyBy Nasdaq OMXMay 15, 2017, 1:04 PM UTC
BusinessSPR Therapeutics Appoints Michael P. Chuisano to Board of DirectorsBy Nasdaq OMXMar 21, 2017, 1:33 PM UTC
BusinessSPR Therapeutics Names Dave Youngberg Vice President of SalesBy Nasdaq OMXJan 17, 2017, 2:30 PM UTC
